1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [PubMed] [Google Scholar]

2. Radecka B, Litwiniuk M. Breast cancer in young women. Ginekol Pol. 2016;87:659–63. [PubMed] [Google Scholar]

3. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast cancer trends in the United States. J. Clin. Oncol. 2007;25:3923–9. [PubMed] [Google Scholar]

4. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2–8. [PMC free article] [PubMed] [Google Scholar]

5. Kim YI. Folate and cancer: a tale of Dr. Jekyll and Mr. Hyde? Am J Clin Nutr. 2018;107:139–42. [PubMed] [Google Scholar]

6. National Cancer Registry Report [Internet] National Health Laboratory Service. 2014 [cited 21/11/2017] Available from: http://www.nioh.ac.za/assets/files/2013NCR.pdf.

7. Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E. Breast cancer risk factors. Prz Menopauzalny. 2015;14:196–202. [PMC free article] [PubMed] [Google Scholar]

9. Cao Y, Willett WC, Rimm EB, Stampfer MJ, Giovannucci EL. Light to moderate intake of alcohol, drinking patterns, and risk of cancer: results from two prospective US cohort studies. BMJ. 2015;351:h4238. [PMC free article] [PubMed] [Google Scholar]

10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. [PubMed] [Google Scholar]

11. da Costa Vieira RA, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. Clinics (Sao Paulo) 2017;72:244–53. [PMC free article] [PubMed] [Google Scholar]

12. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17:43–6. [PubMed] [Google Scholar]

13. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24:1495–506. [PubMed] [Google Scholar]

14. Ramathuba DU, Ratshirumbi CT, Mashamba TM. Knowledge, attitudes and practices toward breast cancer screening in a rural South African community. Curationis. 2015;38 [PMC free article] [PubMed] [Google Scholar]

15. Cumber SN, Nchanji KN, Tsoka-Gwegwenia JN. Breast cancer among women in sub-Saharan Africa: prevalence and a situational analysis. Southern African Journal of Gynaecological Oncology. 2017;9:35–7. [Google Scholar]

16. Nojilana B, Bradshaw D, Pillay-van Wyk V, Msemburi W, Somdyala N, Joubert JD, Groenewald P, Laubscher R, Dorrington RE. Persistent burden from non-communicable diseases in South Africa needs strong action. S Afr Med J. 2016;106:23–4. [PubMed] [Google Scholar]

17. NCI. Surveillance, Epidemiology, and End Results Program. Breast Cancer Statistics. 2019. [Available from: https://seer.cancer.gov/statfacts/html/common.html]

18. Pace LE, Shulman LN. Breast cancer in sub-saharan Africa: challenges and opportunities to reduce mortality. Oncologist. 2016;21:739–44. [PMC free article] [PubMed] [Google Scholar]

19. Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J. Clin. Oncol. 2001;19(Suppl):125S–7S. [PubMed] [Google Scholar]

20. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, Parkin DM. Cancer burden in Africa and opportunities for prevention. Cancer. 2012;118:4372–84. [PubMed] [Google Scholar]

21. Gerend MA, Pai M. Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev. 2008;17:2913–23. [PubMed] [Google Scholar]

22. Foy KC, Fisher JL, Lustberg MB, Gray DM, DeGraffinreid CR, Paskett ED. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. NPJ Breast Cancer. 2018;4:7. [PMC free article] [PubMed] [Google Scholar]

23. Brinton LA, Awuah B, Nat Clegg-Lamptey J, Wiafe-Addai B, Ansong D, Nyarko KM, Wiafe S, Yarney J, Biritwum R, Brotzman M, Adjei AA, Adjei E, Aitpillah F, Edusei L, Dedey F, Nyante SJ, Oppong J, Osei-Bonsu E, Titiloye N, Vanderpuye V, Brew Abaidoo E, Arhin B, Boakye I, Frempong M, Ohene Oti N, Okyne V, Figueroa JD. Design considerations for identifying breast cancer risk factors in a population-based study in Africa. Int J Cancer. 2017;140:2667–77. [PMC free article] [PubMed] [Google Scholar]

24. Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat. 2002;74:199–211. [PubMed] [Google Scholar]

25. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer. 2008;98:277–81. [PMC free article] [PubMed] [Google Scholar]

26. Dickens C, Pfeiffer RM, Anderson WF, Duarte R, Kellett P, Schüz J, Kielkowski D, McCormack VA. Investigation of breast cancer sub-populations in black and white women in South Africa. Breast Cancer Res Treat. 2016;160:531–7. [PubMed] [Google Scholar]

27. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26:444–57. [PubMed] [Google Scholar]

28. Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13:e95–e102. [PubMed] [Google Scholar]

29. Cecilio AP, Takakura ET, Jumes JJ, Dos Santos JW, Herrera AC, Victorino VJ, Panis C. Breast cancer in Brazil: epidemiology and treatment challenges. Breast Cancer (Dove Med Press) 2015;7:43–9. [PMC free article] [PubMed] [Google Scholar]

30. Werutsky G, Nunes P, Barrios C. Locally advanced breast cancer in Brazil: current status and future perspectives. Ecancermedicalscience. 2019;13:895. [PMC free article] [PubMed] [Google Scholar]

31. Santos MO. Estimate 2018: cancer incidence in Brazil Revista Brasileira de Cancerologia. 2018;64:119–20. [Google Scholar]

32. Diniz CSG, Pellini ACG, Ribeiro AG, Tedardi MV, Miranda MJ, Touso MM, Baquero OS, Santos PCD, Chiaravalloti-Neto F. Breast cancer mortality and associated factors in Sao Paulo State, Brazil: an ecological analysis. BMJ Open. 2017;7:e016395. [PMC free article] [PubMed] [Google Scholar]

33. Fan L, Goss PE, Strasser-Weippl K. Current status and future projections of breast cancer in Asia. Breast Care (Basel) 2015;10:372–8. [PMC free article] [PubMed] [Google Scholar]

34. Mubarik S, Malik SS, Wang Z, Li C, Fawad M, Yu C. Recent insights into breast cancer incidence trends among four Asian countries using age-period-cohort model. Cancer Manag Res. 2019;11:8145–55. [PMC free article] [PubMed] [Google Scholar]

35. Zuo TT, Zheng RS, Zeng HM, Zhang SW, Chen WQ. Female breast cancer incidence and mortality in China, 2013. Thorac Cancer. 2017;8:214–8. [PMC free article] [PubMed] [Google Scholar]

36. Denis GV, Palmer JR. “Obesity-associated” breast cancer in lean women: metabolism and inflammation as critical modifiers of risk. Cancer Prev Res (Phila) 2017;10:267–9. [PMC free article] [PubMed] [Google Scholar]

37. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019;11:151–64. [PMC free article] [PubMed] [Google Scholar]

38. Ayeni OA, Norris SA, Joffe M, Cubasch H, Nietz S, Buccimazza I, Singh U, Čačala S, Stopforth L, Chen WC, McCormack VA, O’Neil DS, Jacobson JS, Neugut AI, Ruff P, Micklesfield LK. The multimorbidity profile of South African women newly diagnosed with breast cancer. Int J Cancer. 2019 [Epub ahead of print] [PMC free article] [PubMed] [Google Scholar]

39. Ayeni OA, Joffe M, Cubasch H, Rinaldi S, Taljaard C, Vorster E, Romieu I, Norris SA. Prevalence of comorbidities in women with and without breast cancer in Soweto, South Africa: results from the SABC study. S Afr Med J. 2019;109:264–71. [PMC free article] [PubMed] [Google Scholar]

40. Maskarinec G, Jacobs S, Park SY, Haiman CA, Setiawan VW, Wilkens LR, Le Marchand L. Type II diabetes, obesity, and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2017;26:854–61. [PMC free article] [PubMed] [Google Scholar]

41. Dietze EC, Chavez TA, Seewaldt VL. Obesity and triple-negative breast cancer: disparities, controversies, and biology. Am J Pathol. 2018;188:280–90. [PMC free article] [PubMed] [Google Scholar]

42. Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH. Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses’ health studies. Int J Cancer. 2016;138:2346–56. [PMC free article] [PubMed] [Google Scholar]

44. Endogenous Hormones and Breast Cancer Collaborative Group. Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoff man-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, Tworoger SS, Vineis P. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14:1009–19. [PMC free article] [PubMed] [Google Scholar]

45. Dall GV, Britt KL. Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol. 2017;7:110. [PMC free article] [PubMed] [Google Scholar]

46. Sampson JN, Falk RT, Schairer C, Moore SC, Fuhrman BJ, Dallal CM, Bauer DC, Dorgan JF, Shu XO, Zheng W, Brinton LA, Gail MH, Ziegler RG, Xu X, Hoover RN, Gierach GL. Association of estrogen metabolism with breast cancer risk in different cohorts of postmenopausal women. Cancer Res. 2017;77:918–25. [PMC free article] [PubMed] [Google Scholar]

47. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006;102:89–96. [PMC free article] [PubMed] [Google Scholar]

48. Cavalieri E, Rogan E. The molecular etiology and prevention of estrogen-initiated cancers: Ockham’s Razor: pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity. Mol Aspects Med. 2014;36:1–55. [PMC free article] [PubMed] [Google Scholar]

49. Lovett JL, Chima MA, Wexler JK, Arslanian KJ, Friedman AB, Yousif CB, Strassmann BI. Oral contraceptives cause evolutionarily novel increases in hormone exposure: a risk factor for breast cancer. Evol Med Public Health. 2017;2017:97–108. [PMC free article] [PubMed] [Google Scholar]

50. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22:1931–43. [PubMed] [Google Scholar]

51. Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015;20:39–50. [PMC free article] [PubMed] [Google Scholar]

52. Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D’Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523:313–7. [PMC free article] [PubMed] [Google Scholar]

53. McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem. 2018;293:1163–77. [PMC free article] [PubMed] [Google Scholar]

54. Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, Hemming J, Wright K, Ashworth A, Swerdlow AJ. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer. 2016;115:607–15. [PMC free article] [PubMed] [Google Scholar]

55. Chlebowski RT, Anderson GL. Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf. 2015;6:45–56. [PMC free article] [PubMed] [Google Scholar]

56. Flores VA, Taylor HS. The effect of menopausal hormone therapies on breast cancer: avoiding the risk. Endocrinol Metab Clin North Am. 2015;44:587–602. [PMC free article] [PubMed] [Google Scholar]

57. De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010;102:1489–95. [PubMed] [Google Scholar]

58. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4. [PubMed] [Google Scholar]

59. Colditz GA. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 2007;9:108. [PMC free article] [PubMed] [Google Scholar]

60. Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. 2009;96:E1–6. [PubMed] [Google Scholar]

61. Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat. 2009;117:223–4. [PubMed] [Google Scholar]

62. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18. [PubMed] [Google Scholar]

63. Chen P, Li C, Li X, Li J, Chu R, Wang H. Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis. Br J Cancer. 2014;110:2327–38. [PMC free article] [PubMed] [Google Scholar]

64. Zhang YF, Shi WW, Gao HF, Zhou L, Hou AJ, Zhou YH. Folate intake and the risk of breast cancer: a dose-response meta-analysis of prospective studies. PLoS One. 2014;9:e100044. [PMC free article] [PubMed] [Google Scholar]

65. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE, Willett WC. A prospective study of folate intake and the risk of breast cancer. JAMA. 1999;281:1632–7. [PubMed] [Google Scholar]

66. Varela-Rey M, Woodhoo A, Martinez-Chantar ML, Mato JM, Lu SC. Alcohol, DNA methylation, and cancer. Alcohol Res. 2013;35:25–35. [PMC free article] [PubMed] [Google Scholar]

67. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr. 2012;3:21–38. [PMC free article] [PubMed] [Google Scholar]

68. Cantarella CD, Ragusa D, Giammanco M, Tosi S. Folate deficiency as predisposing factor for childhood leukaemia: a review of the literature. Genes Nutr. 2017;12:14. [PMC free article] [PubMed] [Google Scholar]

69. Zakhari S, Hoek JB. Epidemiology of moderate alcohol consumption and breast cancer: association or causation? Cancers (Basel) 2018;10 [PMC free article] [PubMed] [Google Scholar]

70. Islam T, Ito H, Sueta A, Hosono S, Hirose K, Watanabe M, Iwata H, Tajima K, Tanaka H, Matsuo K. Alcohol and dietary folate intake and the risk of breast cancer: a case-control study in Japan. Eur J Cancer Prev. 2013;22:358–66. [PubMed] [Google Scholar]

71. McDonald JA, Goyal A, Terry MB. Alcohol intake and breast cancer risk: weighing the overall evidence. Curr Breast Cancer Rep. 2013;5 [PMC free article] [PubMed] [Google Scholar]

72. Ritchie H, Roser M. Alcohol Consumption. 2019. [Available from: https://ourworldindata.org/alcohol-consumption

citation]

73. Qian F, Ogundiran T, Hou N, Ndom P, Gakwaya A, Jombwe J, Morhason-Bello I, Adebamowo C, Ademola A, Ojengbede O, Olopade OI, Huo D. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. PLoS One. 2014;9:e106908. [PMC free article] [PubMed] [Google Scholar]

74. Kispert S, McHowat J. Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer. Breast Cancer (Dove Med Press) 2017;9:127–32. [PMC free article] [PubMed] [Google Scholar]

75. Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in the generations study cohort. Breast Cancer Res. 2017;19:118. [PMC free article] [PubMed] [Google Scholar]

76. Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Altas. 3rd edition 2009. [Google Scholar]

77. Glynn T, Seffrin JR, Brawley OW, Grey N, Ross H. The globalization of tobacco use: 21 challenges for the 21st century. CA Cancer J Clin. 2010;60:50–61. [PubMed] [Google Scholar]

78. Malik A, Jeyaraj PA, Shankar A, Rath GK, Mukhopadhyay S, Kamal VK. Passive smoking and breast cancer-a suspicious link. Asian Pac J Cancer Prev. 2015;16:5715–9. [PubMed] [Google Scholar]

79. Li B, Wang L, Lu MS, Mo XF, Lin FY, Ho SC, Zhang CX. Passive smoking and breast cancer risk among non-smoking women: a case-control study in China. PLoS One. 2015;10:e0125894. [PMC free article] [PubMed] [Google Scholar]

80. Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast cancer following radiation for hodgkin lymphoma: clinical scenarios and risk-reducing strategies. Oncology (Williston Park) 2016;30:1063–70. [PubMed] [Google Scholar]

81. Manzo V, Dirbas F, Telli ML. Breast cancer after hodgkin lymphoma: the price of success. Oncology (Williston Park) 2016;30:1072–3. [PubMed] [Google Scholar]

82. Bakkach J, Mansouri M, Loudiyi A, Nourouti NG, Barakat A, Mechita MB. Secondary breast cancer after Hodgkin lymphoma: a case report and literature review. Ecancermedicalscience. 2018;12:810. [PMC free article] [PubMed] [Google Scholar]

83. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van’t Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–37. [PubMed] [Google Scholar]

84. Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE GENEPSO; EMBRACE; HEBON. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) BMJ. 2012;345:e5660. [PMC free article] [PubMed] [Google Scholar]

85. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254–8. [PubMed] [Google Scholar]

86. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33. [PubMed] [Google Scholar]

87. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543–61. [PMC free article] [PubMed] [Google Scholar]

88. Abdulrashid K, AlHussaini N, Ahmed W, Thalib L. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019;19:256. [PMC free article] [PubMed] [Google Scholar]

89. Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol. 2018;23:36–44. [PubMed] [Google Scholar]

90. Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27:1532–8. [PMC free article] [PubMed] [Google Scholar]

91. Foulkes WD, Sugano K. BRCA2: a grown-up cancer susceptibility gene. Endocr Relat Cancer. 2016;23:E1–3. [PubMed] [Google Scholar]

92. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291–9. [PMC free article] [PubMed] [Google Scholar]

93. Ellsworth DL, Turner CE, Ellsworth RE. A review of the hereditary component of triple negative breast cancer: high- and moderate-penetrance breast cancer genes, low-penetrance loci, and the role of nontraditional genetic elements. J Oncol. 2019;2019:4382606. [PMC free article] [PubMed] [Google Scholar]

94. Wendt C, Margolin S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol. 2019;58:135–46. [PubMed] [Google Scholar]

95. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165:193–200. [PMC free article] [PubMed] [Google Scholar]

96. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat. 2014;144:185–92. [PubMed] [Google Scholar]

97. Kudela E, Samec M, Kubatka P, Nachajova M, Laucekova Z, Liskova A, Dokus K, Biringer K, Simova D, Gabonova E, Dankova Z, Biskupska Bodova K, Zubor P, Trog D. Breast cancer in young women: status Quo and advanced disease management by a predictive, preventive, and personalized approach. Cancers (Basel) 2019;11 [PMC free article] [PubMed] [Google Scholar]

98. Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, Cubasch H, Poppe B, Van Maerken T, Crombez B, Coene I, Kerr R, Slabbert JP, Vral A, Krause A, Baeyens A, Claes KB. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer. 2015;15:912. [PMC free article] [PubMed] [Google Scholar]

99. Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, Wang MY, Liu CY, Cheng FT, Yeh MH, Li HY, Yang YH, Hsu YH, Fan SC, Li LY, Yu SL, Chang KJ, Chen PL, Ni YH, Huang CS. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget. 2016;7:8310–20. [PMC free article] [PubMed] [Google Scholar]

100. Kim HJ, Jung S, Eliassen AH, Chen WY, Willett WC, Cho E. Alcohol consumption and breast cancer risk in younger women according to family history of breast cancer and folate intake. Am J Epidemiol. 2017;186:524–31. [PMC free article] [PubMed] [Google Scholar]

101. Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van Rensburg EJ. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer. 2004;110:677–82. [PubMed] [Google Scholar]

102. Sluiter MD, van Rensburg EJ. Large genomic rearrangement of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2010;125:325–49. [PubMed] [Google Scholar]

103. Kim H, Choi DH. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J Breast Cancer. 2013;16:357–65. [PMC free article] [PubMed] [Google Scholar]

104. Wiesman C, Rose E, Grant A, Zimilover A, Klugman S, Schreiber-Agus N. Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population. Genet Med. 2017;19:529–36. [PubMed] [Google Scholar]

105. Janavicius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1:397–412. [PMC free article] [PubMed] [Google Scholar]

106. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54. [PubMed] [Google Scholar]

107. Pellegrini L, Venkitaraman A. Emerging functions of BRCA2 in DNA recombination. Trends Biochem Sci. 2004;29:310–6. [PubMed] [Google Scholar]

108. Balmana J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 2011;1:29–34. [PubMed] [Google Scholar]

110. Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016;15:215–9. [PMC free article] [PubMed] [Google Scholar]

111. Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15:248–54. [PMC free article] [PubMed] [Google Scholar]

112. Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 2018;9:909. [PMC free article] [PubMed] [Google Scholar]

113. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N TNT Trial TMG; BCSC (UK) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234–8. [PMC free article] [PubMed] [Google Scholar]

114. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86. [PMC free article] [PubMed] [Google Scholar]

115. Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J. Clin. Oncol. 2014;32:1093–4. [PubMed] [Google Scholar]

116. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S, Oktay K. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra21. [PMC free article] [PubMed] [Google Scholar]

117. Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119:1652–9. [PMC free article] [PubMed] [Google Scholar]

118. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–4. [PubMed] [Google Scholar]

119. Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52. [PMC free article] [PubMed] [Google Scholar]

120. Walker F, Kermorgant S, Daraï E, Madelenat P, Cremieux AC, Hénin D, Lehy T. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res. 2003;9:273–84. [PubMed] [Google Scholar]

121. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113:678–82. [PubMed] [Google Scholar]

122. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43. [PubMed] [Google Scholar]

123. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012;106:304–10. [PubMed] [Google Scholar]

124. Zhao X, Qu J, Hui Y, Zhang H, Sun Y, Liu X, Zhao X, Zhao Z, Yang Q, Wang F, Zhang S. Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. Oncotarget. 2017;8:56758–67. [PMC free article] [PubMed] [Google Scholar]

125. Hanna JA, Bordeaux J, Rimm DL, Agarwal S. The function, proteolytic processing, and histopathology of Met in cancer. Adv Cancer Res. 2009;103:1–23. [PubMed] [Google Scholar]

126. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–48. [PubMed] [Google Scholar]

127. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103. [PubMed] [Google Scholar]

128. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–62. [PubMed] [Google Scholar]

129. Walker SR, Xiang M, Frank DA. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol. 2014;382:616–21. [PMC free article] [PubMed] [Google Scholar]

130. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138:2570–8. [PMC free article] [PubMed] [Google Scholar]

131. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19:5662–79. [PubMed] [Google Scholar]

132. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105. [PubMed] [Google Scholar]

133. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276:45443–55. [PubMed] [Google Scholar]

134. Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38:195. [PMC free article] [PubMed] [Google Scholar]

135. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293–325. [PubMed] [Google Scholar]

136. Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol. 2011;2011:284584. [PMC free article] [PubMed] [Google Scholar]

137. Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat. 2018;170:213–9. [PubMed] [Google Scholar]

138. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008. [PMC free article] [PubMed] [Google Scholar]

139. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749–58. [PMC free article] [PubMed] [Google Scholar]

140. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010;2:a000935. [PMC free article] [PubMed] [Google Scholar]

141. Rueda-Rincon N, Bloch K, Derua R, Vyas R, Harms A, Hankemeier T, Khan NA, Dehairs J, Bagadi M, Binda MM, Waelkens E, Marine JC, Swinnen JV. p53 attenuates AKT signaling by modulating membrane phospholipid composition. Oncotarget. 2015;6:21240–54. [PMC free article] [PubMed] [Google Scholar]

142. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10. [PubMed] [Google Scholar]

143. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol. 2010;2:a001040. [PMC free article] [PubMed] [Google Scholar]

144. Liang Y, Liu J, Feng Z. The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci. 2013;3:9. [PMC free article] [PubMed] [Google Scholar]

145. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192:209–18. [PMC free article] [PubMed] [Google Scholar]

146. Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, Ghigna C. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol. 2013;2013:962038. [PMC free article] [PubMed] [Google Scholar]

147. Yang Q, Zhao J, Zhang W, Chen D, Wang Y. Aberrant alternative splicing in breast cancer. J Mol Cell Biol. 2019;11:920–9. [PMC free article] [PubMed] [Google Scholar]

148. Martinez-Montiel N, Anaya-Ruiz M, Perez-Santos M, Martinez-Contreras RD. Alternative splicing in breast cancer and the potential development of therapeutic tools. Genes (Basel) 2017;8 [PMC free article] [PubMed] [Google Scholar]

149. Xiping Z, Qingshan W, Shuai Z, Hongjian Y, Xiaowen D. A summary of relationships between alternative splicing and breast cancer. Oncotarget. 2017;8:51986–93. [PMC free article] [PubMed] [Google Scholar]

150. Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O’Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK kConFab Investigators. D’Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. The BRCA1-Delta11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 2016;76:2778–90. [PMC free article] [PubMed] [Google Scholar]

152. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16:49. [PMC free article] [PubMed] [Google Scholar]

153. Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS. Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Mol Cell Endocrinol. 2017;440:138–50. [PMC free article] [PubMed] [Google Scholar]

154. Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia. 2000;5:271–81. [PubMed] [Google Scholar]

155. Jonsson P, Katchy A, Williams C. Support of a bi-faceted role of estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer cells. Endocr Relat Cancer. 2014;21:143–60. [PMC free article] [PubMed] [Google Scholar]

156. Koedoot E, Wolters L, van de Water B, Devedec SEL. Splicing regulatory factors in breast cancer hallmarks and disease progression. Oncotarget. 2019;10:6021–6037. [PMC free article] [PubMed] [Google Scholar]

157. Sun W, Gu C, Xia M, Zhong G, Song H, Guo J. Significance of estrogen receptor subtypes in breast tumorigenesis and progression. Tumour Biol. 2014;35:9111–7. [PubMed] [Google Scholar]

158. Rajapaksa G, Nikolos F, Bado I, Clarke R, Gustafsson JA, Thomas C. ERbeta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. Oncogene. 2015;34:4130–41. [PubMed] [Google Scholar]

159. Baek JM, Chae BJ, Song BJ, Jung SS. The potential role of estrogen receptor beta2 in breast cancer. Int J Surg. 2015;14:17–22. [PubMed] [Google Scholar]

160. Smith LD, Leme de Calais F, Raponi M, Mellone M, Buratti E, Blaydes JP, Baralle D. Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action. Int J Cancer. 2017;140:1564–70. [PubMed] [Google Scholar]

161. Park S, Brugiolo M, Akerman M, Das S, Urbanski L, Geier A, Kesarwani AK, Fan M, Leclair N, Lin KT, Hu L, Hua I, George J, Muthuswamy SK, Krainer AR, Anczuków O. Differential functions of splicing factors in mammary transformation and breast cancer metastasis. Cell Rep. 2019;29:2672–88. e7. [PMC free article] [PubMed] [Google Scholar]

162. Takeiwa T, Mitobe Y, Ikeda K, Horie-Inoue K, Inoue S. Roles of splicing factors in hormone-related cancer progression. Int J Mol Sci. 2020;21 [PMC free article] [PubMed] [Google Scholar]

163. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010;102:1224–37. [PMC free article] [PubMed] [Google Scholar]

164. Kim H, Kim HH, Han B, Kim KH, Han K, Nam H, et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. Lancet Digital Health. 2020;2:e138–48. [PubMed] [Google Scholar]

165. Kim SH, Kim HH, Moon WK. Automated breast ultrasound screening for dense breasts. Korean J Radiol. 2020;21:15–24. [PMC free article] [PubMed] [Google Scholar]

166. Corsetti V, Houssami N, Ferrari A, Ghirardi M, Bellarosa S, Angelini O, Bani C, Sardo P, Remida G, Galligioni E, Ciatto S. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer. 2008;44:539–44. [PubMed] [Google Scholar]

167. Broeders MJM, Allgood P, Duffy SW, Hofvind S, Nagtegaal ID, Paci E, Moss SM, Bucchi L. The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review. BMC Cancer. 2018;18:860. [PMC free article] [PubMed] [Google Scholar]

168. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005. [PubMed] [Google Scholar]

169. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012;36:237–48. [PubMed] [Google Scholar]

170. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015;385:977–1010. [PMC free article] [PubMed] [Google Scholar]

171. Synman L. Breast cancer mammography screening for low-risk women in South Africa. Southern African Journal of Gynaecological Oncology. 2010;2:69–70. [Google Scholar]

172. Cazap E. Breast cancer in latin America: a map of the disease in the region. Am Soc Clin Oncol Educ Book. 2018;38:451–6. [PubMed] [Google Scholar]

173. Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 2016;28:1–11. [PMC free article] [PubMed] [Google Scholar]

174. Klarenbach S, Sims-Jones N, Lewin G, Singh H, Thériault G, Tonelli M, Doull M, Courage S, Garcia AJ, Thombs BD Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer. CMAJ. 2018;190:E1441–E51. [PMC free article] [PubMed] [Google Scholar]

175. Ely S, Vioral AN. Breast cancer overview. Plast Surg Nurs. 2007;27:128–33. quiz 34-5. [PubMed] [Google Scholar]

176. Bhoo-Pathy N, Yip CH, Hartman M, Uiterwaal CS, Devi BC, Peeters PH, Taib NA, van Gils CH, Verkooijen HM. Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer. 2013;49:703–9. [PubMed] [Google Scholar]

177. Tfayli A, Temraz S, Abou Mrad R, Shamseddine A. Breast cancer in low- and middle-income countries: an emerging and challenging epidemic. J Oncol. 2010;2010:490631. [PMC free article] [PubMed] [Google Scholar]

178. Kantelhardt EJ, Muluken G, Sefonias G, Wondimu A, Gebert HC, Unverzagt S, Addissie A. A review on breast cancer care in Africa. Breast Care (Basel) 2015;10:364–70. [PMC free article] [PubMed] [Google Scholar]

179. Martei YM, Pace LE, Brock JE, Shulman LN. Breast cancer in low- and middle-income countries: why we need pathology capability to solve this challenge. Clin Lab Med. 2018;38:161–73. [PMC free article] [PubMed] [Google Scholar]

180. Mulder N. Development to enable precision medicine in Africa. Per Med. 2017;14:467–70. [PubMed] [Google Scholar]

181. Bishr MK, Zaghloul MS. Radiation therapy availability in africa and latin america: two models of low and middle income countries. Int J Radiat Oncol Biol Phys. 2018;102:490–8. [PubMed] [Google Scholar]

182. IAEA. Radiotherapy in cancer care: facing the global challenge. 2017 [Google Scholar]

183. Vanderpuye V, Grover S, Hammad N, PoojaPrabhakar , Simonds H, Olopade F, Stefan DC. An update on the management of breast cancer in Africa. Infect Agent Cancer. 2017;12:13. [PMC free article] [PubMed] [Google Scholar]

184. Ali SH, Somashekhar SP, Kumar AN. Rate of breast-conserving surgery vs mastectomy in breast cancer: a tertiary care centre experience from South India. Indian J Surg Oncol. 2019;10:72–76. [PMC free article] [PubMed] [Google Scholar]

185. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308–24. [PMC free article] [PubMed] [Google Scholar]

186. Huang NS, Liu MY, Chen JJ, Yang BL, Xue JY, Quan CL, Mo M, Liu GY, Shen ZZ, Shao ZM, Wu J. Surgical management of breast cancer in China: a 15-year single-center retrospective study of 18,502 patients. Medicine (Baltimore) 2016;95:e4201. [PMC free article] [PubMed] [Google Scholar]

187. Cubasch H, Joffe M, Ruff P, Dietz D, Rosenbaum E, Murugan N, Chih MT, Ayeni O, Dickens C, Crew K, Jacobson JS, Neugut A. Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PLoS One. 2017;12:e0182125. [PMC free article] [PubMed] [Google Scholar]

188. Rivera-Franco MM, Leon-Rodriguez E. Delays in breast cancer detection and treatment in developing countries. Breast Cancer (Auckl) 2018;12:1178223417752677. [PMC free article] [PubMed] [Google Scholar]

189. Unger-Saldana K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5:465–77. [PMC free article] [PubMed] [Google Scholar]

190. Romeiro Lopes TC, Gravena AAF, Demitto MO, Borghesan DHP, Dell’Agnolo CM, Brischiliari SCR, Carvalho MDB, Pelloso SM. Delay in diagnosis and treatment of breast cancer among women attending a reference service in brazil. Asian Pac J Cancer Prev. 2017;18:3017–23. [PMC free article] [PubMed] [Google Scholar]

191. Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E. Delays in diagnosis and treatment of breast cancer: a safety-net population profile. J Natl Compr Canc Netw. 2018;16:1451–7. [PubMed] [Google Scholar]

192. Li Y, Zhou Y, Mao F, Guan J, Lin Y, Wang X, Zhang Y, Zhang X, Shen S, Sun Q. The influence on survival of delay in the treatment initiation of screening detected non-symptomatic breast cancer. Sci Rep. 2019;9:10158. [PMC free article] [PubMed] [Google Scholar]

193. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. [PubMed] [Google Scholar]

194. GLOBOCAN. Global Breast Cancer Fact Sheet. 2018. [Available from: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf]